Werewolf Therapeutics, Inc.
HOWL · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.02 | 0.08 | 0.01 | -0.01 |
| FCF Yield | -88.01% | -24.26% | -74.71% | -13.33% |
| EV / EBITDA | 0.15 | -1.70 | 1.08 | -3.72 |
| Quality | ||||
| ROIC | -64.95% | -24.74% | -40.52% | -29.42% |
| Gross Margin | 3.77% | 91.15% | 84.70% | 0.00% |
| Cash Conversion Ratio | 0.80 | 0.87 | 0.75 | 0.86 |
| Growth | ||||
| Revenue 3-Year CAGR | -51.38% | – | – | – |
| Free Cash Flow Growth | -69.08% | 24.49% | -1.92% | -126.09% |
| Safety | ||||
| Net Debt / EBITDA | 1.15 | 2.54 | 2.23 | 2.88 |
| Interest Coverage | -15.81 | -12.90 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -610.68 | -251.73 | -23.37 | -1,011.57 |